- 著者
- 
             
             宮澤 修平
             
             岡野 和夫
             
             下村 直之
             
             / 川原 哲也
             
             浅野 修
             
             吉村 寛幸
             
             宮本 光明
             
             佐久間 義範
             
             村本 賢三
             
             尾葉石 浩
             
             原田 耕吉
             
             梶間 隆
             
             山田 浩司
             
             角田 創
             
             片山 敏
             
             阿部 信也
             
             浅川 直樹
             
             左右田 茂
             
             堀江 透
             
             里 忠
             
             町田 善正
             
             片山 幸一
             
             山津 功
             
             Isao YAMATSU
             
          
- 出版者
- The Pharmaceutical Society of Japan
- 雑誌
- Chemical and Pharmaceutical Bulletin (ISSN:00092363)
- 巻号頁・発行日
- vol.39, no.12, pp.3215-3220, 1991-12-25 (Released:2008-03-31)
- 参考文献数
- 27
- 被引用文献数
- 
             
             6
             
             
             9
             
             
          
        
        A series of triazolodiazepines was synthesized and evaluated for anti-platelet activating factor (PAF) activities. Structure-activity relationship (SAR) studies on this series revealed that the introduction of a methyl group into the 8-position of the thienodiazepine nucleus can lead to a lengthening of the duration of action. Introduction of a methyl group produced an asymmetric center and the enantiomers so formed were separated with an optical resolving column. In the in vitro assay system, the (+)-isomers displayed 50-200 times more potent anti-PAF activity than the (-)-isomers. After comparison of toxicology and pharmacokinetics, (+)-6-(2-chlorophenyl)-3-cyclopropanecarbonyl-8, 11-dimethyl-2, 3, 4, 5-tetrahydro-8H-pyrido[4', 3' : 4, 5]thieno[3, 2-f][1, 2, 4]triazolo[4, 3-a][1, 4]diazepine (35(+)-isomer, E6123) was selected from among the compounds synthesized as a candidate for clinical study.